Author

Christoper Ott

Broad Institute

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Assay:ChIP-seq· 1 Research Focus:chromatin & epigenetic regulation· 1 Assay:DNA methylation· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

Adrian P. BrackeniD· 1 shared Anthony M. DohertyiD· 1 shared Christopher R. VakociD· 1 shared Craig MongeriD· 1 shared Eimear LaganiD· 1 shared Gerard L. BrieniD· 1 shared Giorgio OlivieroiD· 1 shared Junwei ShiiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Adrian P. BrackenORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

SS18-SSX co-opts P300 to sustain oncogenic transcription independent of SWI/SNF activity

Anthony M. Doherty, Eimear Lagan, Richard J. R. Elliott, Kieran J. Wynne, Craig Monger, Adrian P. Bracken, Junwei Shi, Christopher R. Vakoc, Scott A. Armstrong, Giorgio Oliviero, Christoper Ott, Neil O. Carragher, Gerard L. Brien

This study shows SS18-SSX sustains oncogenic transcription without needing SWI/SNF activity, identifies P300 as a critical co-factor, and demonstrates targeting P300 or SWI/SNF as therapeutic strategies.

bioRxiv · Jan 27, 2026 · PreprintCancer Biology